May 25, 2023 10:24 AM EDT

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Oxford BioTherapeutics said Thursday that it has extended its second collaboration with Boehringer Ingelheim for another two years. The biotech said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

Associate Editor

Senior Reporter

Sign up to read this article for free.

more like this

Boehringer Ingelheim extends 2020 collab with Oxford BioTherapeutics; European biotechs claim positive PhI I/O data